$3.99-1.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Just reported
From Opus Genetics, Inc.'s results release of November 10, 2026; its quarterly report has since been filed.
Actual
$1.1M
-63% y/y
+51% q/q
Guided
—
No guide given
Actual
-$0.46
Guided
—
No guide given
Actual
-$19.2M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.1M | $3.1M | -63.07% |
| Profit | -$46.5M | -$17.5M | -166.39% |
| Profit per share | -$0.46 | -$0.25 | -84.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Opus Genetics, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The last several months have marked a period of tremendous advancement for our leading gene therapy programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Opus Genetics, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.